Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 25, 2016

View Archived Issues

EDP-305 is a novel potent FXR agonist with promising efficacy in vitro and in vivo

AstraZeneca patents FLAP and leukotriene synthesis inhibitors

Mutabilis discloses beta-lactamase inhibitors

Entyvio receives positive reimbursement recommendation in Canada

Hepatitis C candidate EDP-494 shows promise in early clinical trial

Novel dexamethasone prodrug ZSJ-0228 has lower systemic exposure, improved safety

Shionogi signs license agreement with Tokushima University for novel type A2 Botulinum toxin

Canadian Stem Cell Network announces funding to support stem cell research

First patient given allogeneic adipose tissue-derived multilineage progenitor cells in phase I study

Kymab raises Series C financing to advance antibody pipeline

NVIDIA Foundation awards grant to TGen to support technology efforts in cancer

Novel BTK mutation may cause ibrutinib resistance

Anavex offers 41-week update from phase IIa study of ANAVEX 2-73 in mild to moderate Alzheimer's

Lysyl oxidase homolog 2 identified as a therapeutic target for liver fibrosis

Verseon describes novel direct thrombin inhibitor VE-1902

Janssen-Cilag seeks approval of guselkumab in Europe

FN1 is significantly upregulated in ASM vs. ISM

AiCuris conducting new preclinical study of AIC-649 with support from NIAID

GlaxoSmithKline begins phase III program for daprodustat in anemia associated with CKD

Researchers test new highly potent FXR agonist, EP-024297

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...